Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

Still think this has little to do with CNAT. Emricasan main target is late stage disease (Cirrhosis). ICPT OCA is targeting early stage NASH fibrosis like a dozen other competitors.
In fact I think that Emricasan will not be very effective in NASH Fibrosis (at least as monotherapy), since it has not proven very effective in Cirrhosis early stages (low Portal pressure and low MELD score).
Fortunately the patients for which it has proven to be effective, are the ones who need it most. And the ones who need it most are the Cirrhosis decompensated patients, ie ca 11% of the 50M plus Liver Cirrhotic patients globally